Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016

The Hemophilia Therapeutics Market is Forecast to Show Slow Growth to 2016

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5
billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the
high price of therapy. The safety and efficacy profiles of the existing therapies are
moderate. The major treatments for hemophilia A include recombinant factor VIII drugs
such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe
hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin),
which stimulates the release of factor VIII and also increases the level of proteins in the
blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from
Baxter Laboratories. BeneFIX is a clotting factor IX.

Current Treatment Options are Moderately Successful in Meeting Market Demand

GlobalData suggests that the hemophilia therapeutics market has moderate unmet
needs in terms of both safety and efficacy. The majority of the drugs available in the
market belong to the substitution of coagulation factor VIII drug class. NovoSeven,
Xyntha and Kogenate FS are the main drugs available to treat hemophilia. Kogenate FS
has been proved highly efficacious while NovoSeven has shown the least side effects.
Kogenate FS is the only FDA-approved drug which increases clotting factor VIII.

For further details please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haemophilia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

Poor Diagnosis of the Disease is a Major Barrier for the Hemophilia Market
The incidence of hemophilia is considered to be underestimated. Indeed, patients may
be seen by several specialists and undergo dangerous investigations and interventions
before the correct diagnosis is made. Most of the old aged patients with acquired
hemophilia are associated with autoimmune diseases or cancer. Apart from
misdiagnoses, acquired hemophilia may be underdiagnosed as many cases of clinically
silent low titer inhibitors may be unrecognized unless patients undergo surgery or
trauma. Hence the low diagnosis rate is major barrier in the hemophilia market.

Strong Pipeline Candidates are Expected to Intensify Future Competition

The hemophilia therapeutics developmental pipeline is strong with about 13 molecules
in various phases of clinical development. Most of the molecules in clinical development
are first-in-class or me-too. There are two first-in-class molecules in Phase III while there
is only one molecule in Phase II. There are two first-in-class molecules in Phase I. There
are five me-too molecules over all the phases of clinical development. Phase III contains
only one me-too molecule. These molecules include substitution of coagulation factor
VIII, thrombin generation and plasma-derived FVIII. Phase II consists of three molecules
out of which two are me-too molecules.

GlobalData, the industry analysis specialist, has released its latest research, “Hemophilia
– Drug Pipeline Analysis and Market Forecasts to 2016” which provides key data,
information and analysis on the osteoporosis market. The report provides a
comprehensive overview of the annualized market data from 2001 to 2009, and
forecasts for seven years to 2016. The research also includes a market characterization,
opportunities, the unmet needs associated with osteoporosis, a competitive
assessment, profiles of the major marketed products and promising drugs in the
pipeline, an overview of the discontinued projects, implications for the future market
competition, and the key players in the osteoporosis market.

For further details please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haemophilia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782